Home › Non-Small Cell Lung Cancer › Washington › Spokane
Non-Small Cell Lung Cancer clinical trials in Spokane, WA
12 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Spokane (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
RecruitingPhase 3
- Local Institution - 0384, Spokane
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Summit Cancer Centers, Spokane
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Medical Oncology Associates - Spokane /ID# 277172, Spokane
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Research Site, Spokane
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
RecruitingPhase 3
- Summit Cancer Treatment Center, Spokane
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RecruitingPhase 1/2
- Providence Sacred Heart Medical Center, Spokane
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RecruitingPhase 1
- Summit Cancer Center, Spokane
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
RecruitingPhase 3
- Medical Oncology Associates - Summit Cancer Centers, Spokane
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RecruitingPhase 3
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RecruitingPhase 1
- Medical Oncology Associates, Spokane
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RecruitingPhase 2
- USA07-0, Spokane
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 105, Spokane
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH56 studies
- Washington, DC55 studies
Other studies in Spokane
- Breast Cancer8 studies
- Ovarian Cancer8 studies
- Colorectal Cancer8 studies
- Parkinson's Disease7 studies
- Prostate Cancer6 studies
- Chronic Lymphocytic Leukemia6 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Cancer (all types)6 studies
- Triple-Negative Breast Cancer5 studies
- Melanoma5 studies
- Macular Degeneration5 studies
- Geographic Atrophy5 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.